Racial and Ethnic Differences in Urine Drug Screening on Labor and Delivery

2022 ◽  
Author(s):  
Mae-Lan Winchester ◽  
Parmida Shahiri ◽  
Emily Boevers-Solverson ◽  
Abigail Hartmann ◽  
Meghan Ross ◽  
...  
Keyword(s):  
Ethnic Differences ◽  
Drug Screening ◽  
Labor And Delivery ◽  
Racial And Ethnic Differences ◽  
Urine Drug ◽  
Urine Drug Screening

scholarly journals 111: Implementing universal urine drug screening upon admission to labor and delivery

2020 ◽  
Vol 222 (1) ◽  
pp. S88-S89
Author(s):  
Lylach Haizler-Cohen ◽  
Vinisha Singhi ◽  
Jonathan Blau ◽  
Justine Galvin ◽  
Gary Fruhman
Keyword(s):  
Drug Screening ◽  
Labor And Delivery ◽  
Urine Drug ◽  
Urine Drug Screening

605 Universal urine drug screening upon admission to labor and delivery - phase 2 study

2021 ◽  
Vol 224 (2) ◽  
pp. S379-S380
Author(s):  
Lylach Haizler-Cohen ◽  
Ana Collins ◽  
Priyadarshani Giri ◽  
Jonathan Blau ◽  
Adi Davidov ◽  
...  
Keyword(s):  
Drug Screening ◽  
Labor And Delivery ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Urine Drug ◽  
Urine Drug Screening

scholarly journals Racial difference in urine drug screening on a labor and delivery unit

2022 ◽  
Vol 226 (1) ◽  
pp. S660
Author(s):  
Abby Schultz ◽  
Preetha Nandi ◽  
Clara Williamson ◽  
Leigh Kowalski ◽  
Ye Chen ◽  
...  
Keyword(s):  
Drug Screening ◽  
Racial Difference ◽  
Labor And Delivery ◽  
Urine Drug ◽  
Delivery Unit ◽  
Labor And Delivery Unit ◽  
Urine Drug Screening

Urine Drug Screening

2001 ◽  
Vol 11 (3) ◽  
pp. 18???22
Author(s):  
Albert Jekelis
Keyword(s):  
Drug Screening ◽  
Urine Drug ◽  
Urine Drug Screening

Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing

2007 ◽  
Vol 33 (1) ◽  
pp. 33-42 ◽  
Author(s):  
William B. Jaffee ◽  
Elisa Trucco ◽  
Sharon Levy ◽  
Roger D. Weiss
Keyword(s):  
Systematic Review ◽  
Drug Screening ◽  
Urine Drug ◽  
Urine Drug Screening

O30: Comparing the performance of HR-TOFMS and immunoassay for urine drug screening

2014 ◽  
Vol 26 (2) ◽  
pp. S18
Author(s):  
M. Sundström ◽  
A. Pelander ◽  
I. Ojanperä
Keyword(s):  
Drug Screening ◽  
Urine Drug ◽  
Urine Drug Screening

Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS, and LC-MS/MS

2021 ◽  
Author(s):  
Andrii Puzyrenko ◽  
Dan Wang ◽  
Randy Schneider ◽  
Greg Wallace ◽  
Sara Schreiber ◽  
...  
Keyword(s):  
Drug Screening ◽  
Forensic Toxicology ◽  
Confirmatory Testing ◽  
Urine Drug ◽  
Screening Assays ◽  
Us Fda ◽  
Urine Specimens ◽  
Abbott Architect ◽  
Designer Benzodiazepines ◽  
Urine Drug Screening

ABSTRACT This study investigated the presence of designer benzodiazepines in 35 urine specimens obtained from emergency department patients undergoing urine drug screening. All specimens showed apparent false-positive benzodiazepine screening results (i.e., confirmatory testing using a 19-component LC-MS/MS panel showed no prescribed benzodiazepines at detectable levels). The primary aims were to identify the possible presence of designer benzodiazepines, characterize the reactivity of commercially available screening immunoassays with designer benzodiazepines, and evaluate the risk of inappropriately ruling out designer benzodiazepine use when utilizing common urine drug screening and confirmatory tests. Specimens were obtained from emergency departments of a single US Health system. Following clinically ordered drug screening using Abbott ARCHITECT c assays and lab-developed LC-MS/MS confirmatory testing, additional characterization was performed for investigative purposes. Specifically, urine specimens were screened using two additional assays (Roche cobas c502, Siemens Dimension Vista) and LC-QTOF-MS to identify presumptively positive species, including benzodiazepines and non-benzodiazepines. Finally, targeted, qualitative LC-MS/MS was performed to confirm the presence of 12 designer benzodiazepines. Following benzodiazepine detection using the Abbott ARCHITECT, benzodiazepines were subsequently detected in 28/35 and 35/35 urine specimens, respectively, using Siemens and Roche assays. LC-QTOF-MS showed the presumptive presence of at least one non-FDA approved benzodiazepine in 30/35 specimens: flubromazolam (12/35), flualprazolam (11/35), flubromazepam (2/35), clonazolam (4/35), etizolam (9/35), metizolam (5/35), nitrazepam (1/35), and pyrazolam (1/35). Two or three designer benzodiazepines were detected concurrently in 13/35 specimens. Qualitative LC-MS/MS confirmed the presence of at least one designer benzodiazepine or metabolite in 23/35 specimens, with 3 specimens unavailable for confirmatory testing. Urine benzodiazepine screening assays from three manufacturers were cross-reactive with multiple non-US FDA-approved benzodiazepines. Clinical and forensic toxicology laboratories using traditionally designed LC-MS/MS panels may fail to confirm the presence of non-US FDA-approved benzodiazepines detected by screening assays, risking inappropriate interpretation of screening results as false-positives.

The Predictive Value of Routine Urine Drug Screening in a High-Risk Obstetric Population

1992 ◽  
Vol 1 (3) ◽  
pp. 117-120 ◽  
Author(s):  
Gary H. Lipscomb ◽  
Brian M. Mercer ◽  
Kitty C. Cashion ◽  
Lynn D. Jackson ◽  
Diana D. Devall ◽  
...  
Keyword(s):  
High Risk ◽  
Drug Screening ◽  
Predictive Value ◽  
Urine Drug ◽  
Obstetric Population ◽  
Urine Drug Screening
Sign in / Sign up

Export Citation Format

Share Document